TScan Therapeutics, Inc. 8-K Filings

TScan Therapeutics, Inc. (TCRX) is executing a major strategic reorganization to prioritize preclinical development of its in vivo solid tumor program and has paused further enrollment in its Phase 3 ALLOHA-2™ study of TSC-101 for heme malignancies due to capital constraints. As part of this shift, the company is eliminating its internal manufacturing organization, significantly reducing its research footprint, and implementing a workforce reduction of approximately 75%, which is expected to generate cumulative cost savings of $55.0 million through the end of 2027. TScan expects to incur about $4.1 million in employee-related charges, largely future cash costs, and believes its cash, cash equivalents and marketable securities as of June 30, 2026 will fund operations into the fourth quarter of 2027.

The company reported encouraging Phase 1 ALLOHA™ data for TSC-101: all 13/13 Cohort C patients currently tracked show complete donor chimerism, with tolerability consistent with post-transplant expectations. Despite this, the heme malignancy and autoimmunity programs are being paused while TScan seeks strategic partnerships. Separately, TScan received a Nasdaq notice that its stock failed to meet the $1.00 Minimum Bid Price Rule, triggering an initial 180-day compliance period to February 23, 2027. The CFO and CMO roles were terminated without cause in connection with the reorganization, and CEO Gavin MacBeath has assumed principal financial and accounting officer duties.

TScan Therapeutics, Inc. (TCRX) reports that Amgen has elected to terminate in its entirety their Research Collaboration and License Agreement, which focused on using TScan’s target discovery platform to identify T‑cell antigens in Crohn’s disease. Amgen is exercising a contractual right to terminate with 90 days’ prior written notice, making the termination effective November 10, 2026, and TScan will incur no early termination penalty. TScan had previously received a $30.0 million non‑refundable upfront payment in 2023; the agreement also contemplated more than $500 million in success‑based milestones and tiered single‑digit royalties on future product sales. After termination, TScan does not expect future milestone or royalty payments from this collaboration unless Amgen or its affiliates or sublicensees continue to exploit product candidates, in which case applicable milestones and royalties would survive under the agreement’s terms.

TScan Therapeutics, Inc. reported second-quarter 2026 results and updated progress across its pipeline. Revenue was $1.1 million, down from $3.1 million a year earlier, reflecting timing of research activities under its Amgen collaboration. Research and development expenses fell to $23.4 million from $32.6 million, and general and administrative expenses declined to $8.1 million from $9.1 million, contributing to a narrower net loss of $30.4 million versus $37.0 million in the prior-year quarter.

Cash and cash equivalents were $100.2 million as of June 30 2026, and the company believes this will fund its operating plan into the second quarter of 2027. This outlook incorporates commencement of a two-year term-loan amortization beginning in the fourth quarter of 2026 after certain non-covenant milestones under its debt agreement were not achieved by June 30 2026. Common stock and pre-funded warrants outstanding totaled 130,025,962 on June 30 2026.

Operationally, TScan dosed the first patient in its Phase 3 ALLOHA-2™ trial of TSC‑101 in heme malignancies, with topline data expected mid‑2028, and reported positive initial Cohort C data from the Phase 1 ALLOHA™ study, including a ~90% first-pass manufacturing success rate using its commercial-ready process and encouraging donor chimerism responses.

TScan Therapeutics reported positive initial data from Cohort C of its ALLOHA™ Phase 1 study of TSC-101 in patients with blood cancers undergoing allogeneic stem cell transplant. TSC-101, made with a commercial-ready process, led to complete donor chimerism in 11 of 14 patients about three weeks after the first infusion, an early signal linked to lower relapse risk. All but one Cohort C patient (93%) showed decreasing recipient chimerism, indicating effective targeting of residual disease, and no relapses have been observed to date. Safety in Cohort C remained manageable, with fewer acute graft-versus-host disease events than the control group and only one grade 1 cytokine release syndrome event resolving after TSC-101. Earlier ALLOHA data showed 100% of TSC-101–treated patients relapse-free at three years in a small subset versus none on control, helping justify a pivotal Phase 3 ALLOHA-2™ trial targeting relapse-free survival. The company plans to start this Phase 3 trial in Q2 2026 and holds enough cash, $128 as of March 31, 2026, to fund operations into the second half of 2027.

TScan Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to increase authorized voting common stock from 300,000,000 to 600,000,000 shares, and the amendment became effective upon filing in Delaware on May 20, 2026.

Katina Dorton and R. Keith Woods were elected as Class II directors to serve until the 2029 annual meeting. Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved an adjournment proposal, though adjournment was not needed.

TScan Therapeutics reported first quarter 2026 results and outlined upcoming clinical milestones. Revenue was $1.0 million for the quarter, down from $2.2 million a year earlier, mainly reflecting timing of work under its Amgen collaboration. Research and development expenses fell to $21.9 million from $29.8 million, and general and administrative expenses edged down to $8.2 million from $8.6 million, leading to a narrower net loss of $28.7 million versus $34.1 million in 2025. Cash and cash equivalents were $128.1 million as of March 31, 2026, and the company believes this will fund its operating plan into the second half of 2027. TScan plans to launch a Phase 3 study of TSC‑101 in AML and MDS in the second quarter of 2026, start a Phase 1 trial of CD45‑targeted candidates TSC‑102‑A01 and TSC‑102‑A03 in the second half of 2026, and share additional ALLOHA™ Phase 1 heme data during 2026.

TScan Therapeutics, Inc. reported a leadership change in its finance organization. Leiden Dworak notified the company of his decision to resign as Vice President of Finance and principal accounting officer, effective April 10, 2026, and the company stated there were no disagreements regarding its operations, policies or practices.

The Board appointed Chief Financial Officer Jason A. Amello to also serve as principal accounting officer effective April 10, 2026. The company noted that Mr. Amello will not receive additional compensation for this added role and referenced its May 14, 2025 definitive proxy statement for information on his background, contracts and related party transactions.

TScan Therapeutics reported fourth-quarter and full-year 2025 results and outlined key clinical milestones. Revenue rose to $2.6M in Q4 2025 from $0.7M a year earlier, and to $10.3M for 2025 from $2.8M in 2024, mainly from its Amgen collaboration.

R&D expenses were $20.0M for Q4 and $114.2M for 2025, while G&A expenses were $6.4M for Q4 and $32.0M for 2025. Net loss narrowed to $23.0M in Q4 2025 from $35.8M in Q4 2024 and was $129.8M for 2025 versus $127.5M in 2024.

The company highlighted positive Phase 1 ALLOHA™ heme data, FDA clearance of INDs for CD45-targeting TSC-102-A01 and TSC-102-A03, completion of Cohort C enrollment, and plans to launch a pivotal trial for TSC-101 and start a Phase 1 study for TSC-102 candidates in 2026. Cash and cash equivalents were $152.4M as of December 31, 2025, which TScan believes will fund its operating plan into the second half of 2027.

TScan Therapeutics, Inc. furnished a new corporate presentation that it plans to use in meetings during the 44th Annual J.P. Morgan Healthcare Conference. The materials are provided as Exhibit 99.1 and are also available in the investor relations section of the company’s website. The presentation is being furnished under a current report on Form 8-K, meaning it is not treated as filed for liability purposes and is not automatically incorporated into other securities law filings unless specifically referenced.

TScan Therapeutics, Inc. approved a targeted retention program for key executives tied to progress in its pivotal trial of TSC-101. The Board, following the Compensation Committee’s recommendation, adopted a key employee retention program that provides cash and potential future equity-based awards under the 2021 Equity Incentive Plan.

Under this program, CEO Gavin MacBeath, Ph.D., CFO Jason A. Amello and CMO Chrystal Louis, M.D., M.P.H., will be eligible for cash awards of $399,000, $170,000 and $250,000, respectively. Half of each cash award is payable upon achievement of a milestone related to advancement of the pivotal trial of TSC-101, and the other half on the first anniversary of that milestone.

Upon achievement of the same milestone, they are also slated to receive equity awards of 1,000,000 RSUs, 270,000 RSUs and 650,000 RSUs, respectively. These RSUs are scheduled to vest 25% on the second anniversary of the milestone and 75% upon the earlier of reporting completion of the pivotal TSC-101 trial or the fourth anniversary of the grant date, subject to continued service and the terms of the plan and award agreements.

TScan Therapeutics (TCRX) filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.

The company notes the information is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically stated.

TScan Therapeutics announced a strategic shift to prioritize its hematologic malignancies program and pause further enrollment in its solid tumor Phase 1 trial. The company will focus preclinical work on in vivo engineering for solid tumors and target discovery in autoimmunity. TScan also implemented a workforce reduction of approximately 30%, or 66 roles, and expects a one-time charge of up to $2.3 million in the quarter ending December 31, 2025.

TScan reported alignment with the FDA on the pivotal study design for TSC-101. The company furnished a press release and slide presentation detailing these updates.

TScan Therapeutics, Inc. furnished an updated corporate presentation that it plans to use in meetings with investors, analysts, and other stakeholders. The presentation reflects revised development and operational milestones, including adjusted timelines for its solid tumor program, updates to its pipeline in both hematologic malignancies and solid tumors, and new information on its target discovery work in autoimmunity.

The presentation is attached as Exhibit 99.1 and is also being made available through the company’s investor relations website, although website materials are not incorporated by reference into this report. The materials are furnished under a regulation disclosure item and are not deemed filed for liability purposes under the securities laws.

TScan Therapeutics, Inc. reported a leadership change in its finance organization. On August 14, 2025, the Board appointed Leiden Dworak, the company’s Vice President of Finance, as Principal Accounting Officer, effective the same day. Jason A. Amello ceased serving in that accounting role but continues as Chief Financial Officer and Principal Financial Officer.

Mr. Dworak, age 41, has been Vice President, Finance since April 2022 and previously served as the company’s Principal Accounting Officer from July 2023 to January 2024. He brings 17 years of finance experience in biotechnology and life sciences, including roles at AVROBIO, Moderna, Merrimack Pharmaceuticals, SeraCare Life Sciences, and Boston Scientific, and holds an MBA from Indiana University. The company states there are no family relationships or related party transactions requiring disclosure in connection with this appointment.

TScan Therapeutics announced it has furnished a press release reporting its financial results for the quarter ended June 30, 2025. The Current Report states the press release is furnished as Exhibit 99.1 and that the information is furnished, not filed, so it is not subject to Section 18 liability or automatically incorporated by reference into other filings. The filing identifies the company as an emerging growth company and confirms its common stock trades under the symbol TCRX on the Nasdaq Global Market. The report is signed on the company’s behalf by Chief Executive Officer Gavin MacBeath.